^
Association details:
| Biomarker: | SLC44A4 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | ASG 5ME (Microtubule inhibitor, SLC44A4-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers
Excerpt:
...35 patients with pancreatic cancer and 15 patients with SLC44A4-positive gastric cancer were enrolled in the study….Patients received ASG-5ME intravenously on Days 1, 8, and 15 of 28-day cycles....Disease control rates lasting 2 months or longer of 33 % and 47 % were observed for pancreatic and gastric cancer patients, respectively, at the MTD.
DOI:
https://doi.org/10.1007/s10637-016-0343-x
